Nalaganje...

Clinical Pharmacokinetic, Pharmacodynamic and Drug-Interaction Profile of the Integrase Inhibitor Dolutegravir

Dolutegravir is a second generation integrase strand transfer inhibitor (INSTI) currently under review by the US FDA for marketing approval. Dolutegravir’s in vitro, protein adjusted 90% inhibitory concentration (IC(90)) for wild-type virus is 0.064 μg/ml, and it retains in vitro anti-HIV 1 activity...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Cottrell, Mackenzie L., Hadzic, Tanja, Kashuba, Angela D.M.
Format: Artigo
Jezik:Inglês
Izdano: 2013
Teme:
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3805712/
https://ncbi.nlm.nih.gov/pubmed/23824675
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40262-013-0093-2
Oznake: Označite
Brez oznak, prvi označite!